高等学校化学学报

高等学校化学学报 ›› 1999, Vol. 20 ›› Issue (S1): 158.

• Electroanalytical Chemistry • 上一篇    下一篇

The Comparison of CA 125 Immunoassay Methods

YAN Gui-Feng1, LIANG Zhi-Chao1, ZHANG Ting-Qing1, JU Huang-Xian2   

  1. 1. Department of Medical Examination, Cancer Hospital and Institute of Jiangsu Province, Nanjing 210009, P. R. China;
    2. Department of Chemistry, Nanjing University, Nanjing 210093, P. R. China
  • 出版日期:1999-12-31 发布日期:1999-12-31
  • 通讯作者: JU Huang-Xian
  • 基金资助:

    supported by Scientific Research Foundation for Returned Overseas Chinese Scholars, Ministry of Education of China and Cancer. Hospital and Institute of Jiangsu Province.

The Comparison of CA 125 Immunoassay Methods

YAN Gui-Feng1, LIANG Zhi-Chao1, ZHANG Ting-Qing1, JU Huang-Xian2   

  1. 1. Department of Medical Examination, Cancer Hospital and Institute of Jiangsu Province, Nanjing 210009, P. R. China;
    2. Department of Chemistry, Nanjing University, Nanjing 210093, P. R. China
  • Online:1999-12-31 Published:1999-12-31
  • Contact: JU Huang-Xian
  • Supported by:

    supported by Scientific Research Foundation for Returned Overseas Chinese Scholars, Ministry of Education of China and Cancer. Hospital and Institute of Jiangsu Province.

PDF (PC)

摘要：

CA 125 is an antigen defined by monoclonal antibody OC 125 and has been widely applied for clinical diagnosis of ovarian cancer Methods based on IRMA, ELISA and CLEIA for detecting CA 125 have been reported. Many instruments for CA 125 assay in clinical practice have been estabilished. However, there have been many discrepancies among different assay methods. In this work, we study the discrepancies in precision, positivity rate, assay linearity and reproducibility between commercially available CA 125 CLEIA and ELISA techniques by comparing with IRMA. The results would provide a scientific basis for choosing a method of CA 125 immunoassay in the diagnosis of ovarian carcinoma and monitoring of response to therapy,with no need of radioactive reagents.

Abstract:

CA 125 is an antigen defined by monoclonal antibody OC 125 and has been widely applied for clinical diagnosis of ovarian cancer Methods based on IRMA, ELISA and CLEIA for detecting CA 125 have been reported. Many instruments for CA 125 assay in clinical practice have been estabilished. However, there have been many discrepancies among different assay methods. In this work, we study the discrepancies in precision, positivity rate, assay linearity and reproducibility between commercially available CA 125 CLEIA and ELISA techniques by comparing with IRMA. The results would provide a scientific basis for choosing a method of CA 125 immunoassay in the diagnosis of ovarian carcinoma and monitoring of response to therapy,with no need of radioactive reagents.

TrendMD: